Vanda Pharmaceuticals (VNDA) EPS (Basic) (2010 - 2026)

Vanda Pharmaceuticals has reported EPS (Basic) for 17 years, with the latest figure at -$0.82 in Q1 2026.

• Quarterly EPS (Basic) fell 61.94% year-over-year to -$0.82 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.03 (down 432.95% YoY) and the FY2025 annual result came in at -$3.74, down 1051.07% from the prior year.
• EPS (Basic) rose to -$0.82 in Q1 2026 per VNDA's latest filing, from -$2.4 in the prior quarter.
• Over five years, EPS (Basic) peaked at $0.12 in Q4 2022 and troughed at -$2.4 in Q4 2025.
• A 5-year average of -$0.28 and a median of -$0.08 in 2024 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2023 and 2024: EPS (Basic) soared 149.14% in 2023, then slumped 3950.99% in 2024.
• Over 5 years, EPS (Basic) stood at $0.12 in 2022, then slumped by 134.29% to -$0.04 in 2023, then slumped by 101.24% to -$0.08 in 2024, then plunged by 2757.17% to -$2.4 in 2025, then surged by 65.94% to -$0.82 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.82, -$2.4, and -$0.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.